Flailing about as so often for a simple, quick answer to a complex problem, President Trump claimed on Wednesday that an experimental drug he received during treatment for Covid-19 is a “cure.”

And he wants to make it free for all Americans, even though it has not been sufficiently tested even to get emergency-use approval from the FDA.

“Now the drugmaker Regeneron’s stock is up sharply — and questions are swirling about the president’s ties to s billionaire CEO,” reports CNN.

The president got the antibody cocktail called REGN-COV2 at Walter Reed National Military Medical Center through a “compassionate use” request that applies only to specific individuals.

The drug is made by the biotech company Regeneron. Trump formerly owned stock in the company, and is acquainted with its billionaire CEO, Dr. Leonard Schleifer, who is a member of Trump’s golf resort in Westchester, NY.

Regeneron’s stock price jumped sharply this week and is up more than 60% for the year, in part because of $450 million in government funding the company got for working on a vaccine for the virus.

Trump made his dramatic announcement in what several news outlets described as a “rambling” 5-minute video post to Twitter, calling it “a blessing in disguise’ from God that he contracted Covid-19 — implying that if he had not fallen ill, doctors wouldn’t have learned of the drug’s effectiveness, The Hill reported.

“’It was unbelievable,’” Trump—who appeared to be wearing makeup and struggled to get his right eye open at times—said in the video,” Forbes reported. The president added that he “felt good immediately” after receiving the drug.

Wednesday appeared to be the first time Trump acknowledged receiving treatment for Covid-19 that’s not available to the general public, the New York Times reported. The video was shot in the White House Rose Garden on Tuesday and was clearly edited before being posted on Twitter.

Trump is also receiving an antiviral drug, remdesivir, made by Gilead Pharmaceuticals — another company in which he has previously owned stock.